Clinical Data Novo Nordisk microRNA drug fluffs its lines in heart failure PharmaphorumA microRNA-targeting drug acquired by Novo Nordisk when it bought Cardior in a $1bn-plus deal has generated disappointing results in heart failure.CardiovascularRead full story pharminent May 11, 2026 (Last updated: May 16, 2026) Pharmaphorum A microRNA-targeting drug acquired by Novo Nordisk when it bought Cardior in a $1bn-plus deal has generated disappointing results in heart failure. Cardiovascular Read full story Post navigation Previous: Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucherNext: Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
